# US 2018/0024146 A1 · Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0024146 A1
- Document ID: US20180024146A1
- Status: Published application
- Kind: A1
- Application number: 15/719,714
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2005-10-11
- Assignees: Blanchette Rockefeller Neurosciences Institute
- Applicants: Blanchette Rockefeller Neurosciences Institute
- Inventors: Tapan Kumar Khan; Daniel L. Alkon
- Web page: https://patentgrep.com/patent/US20180024146A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2800/2821: Alzheimer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the. Alzheimer's Disease-specific molecular biomarkers disclosed herein.

## Claims

### Claim at position 1

1-107. (canceled)

### Claim 108

A method for diagnosing Alzheimer's disease in a human subject comprising the steps of
(a) culturing subject-derived skin fibroblasts in the presence of bradykinin; and
(b) determining the normalized amounts of phosphorylated Erk1 and phosphorylated Erk2 in the resulting fibroblasts,
whereby the subject is afflicted with Alzheimer's disease if [pErk1bradykinin]/[pErk2bradykinin] minus [pErk1vehicle]/[pErk2vehicle] is greater than zero, wherein (i) [pErk1bradykinin] and [pErk2bradykinin] are the normalized amounts of phosphorylated Erk1 and phosphorylated Erk2 in the fibroblasts cultured with bradykinin, respectively, and (ii) [pErk1vehicle] and [pErk2vehicle] are the normalized amounts of phosphorylated Erk1 and phosphorylated Erk2 in subject-derived skin fibroblasts cultured in the absence of bradykinin, respectively.

### Claim 109 (depends on 108)

The method of claim 108, wherein the subject is afflicted with Alzheimer's disease if [pErk1bradykinin]/[pErk2bradykinin] minus [pErk1vehicle]/[PErk2vehicle] is greater than 0.02 and less than 0.4.

### Claim 110 (depends on 108)

The method of claim 108, wherein determining the normalized amounts of phosphorylated Erk1 and phosphorylated Erk2 is performed using an immunofluorescent assay.
